A Study of Patient Preference Between Cabazitaxel and Docetaxel in First-line Chemotherapy for Metastatic Castrate-resistant Prostate Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Aug 2019
Price : $35 *
At a glance
- Drugs Cabazitaxel (Primary) ; Docetaxel (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms CABA-DOC; CABADOC
- 04 Jun 2019 Final results presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
- 07 Aug 2017 Planned End Date changed from 1 May 2017 to 1 Apr 2018.